Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Juul Holst

Showing results (1-10 of 396) with videos related to

Pageof 40
Sort By:
Lancet (London, England)|June 13, 2019
Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?Jens Juul Holst
Journal of Diabetes|January 18, 2012
Incretin based therapies: do they hold their promise?Jens Juul Holst
Results and Problems in Cell Differentiation|December 5, 2009
Glucagon and glucagon-like peptides 1 and 2Jens Juul Holst
Ugeskrift for Laeger|October 22, 2010
[Cardiac effects of glucagon-like peptide 1]Jens Juul Holst
The Journal of Physiology|November 9, 2024
Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetesJens Juul Holst
Nature Metabolism|August 19, 2024
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight managementJens Juul Holst
Diabetologia|July 4, 2013
Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?Jens Juul Holst
Current Opinion in Pharmacology|October 29, 2013
Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgeryJens Juul Holst
Frontiers in Endocrinology|May 14, 2019
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes TherapyJens Juul Holst
Physiological Reviews|October 12, 2007
The physiology of glucagon-like peptide 1Jens Juul Holst
Pageof 40

Showing results (1-10 of 396) with videos related to

Sort By:
Pageof 40
Lancet (London, England)|June 13, 2019
Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?Jens Juul Holst
Journal of Diabetes|January 18, 2012
Incretin based therapies: do they hold their promise?Jens Juul Holst
Results and Problems in Cell Differentiation|December 5, 2009
Glucagon and glucagon-like peptides 1 and 2Jens Juul Holst
Ugeskrift for Laeger|October 22, 2010
[Cardiac effects of glucagon-like peptide 1]Jens Juul Holst
The Journal of Physiology|November 9, 2024
Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetesJens Juul Holst
Nature Metabolism|August 19, 2024
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight managementJens Juul Holst
Diabetologia|July 4, 2013
Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?Jens Juul Holst
Current Opinion in Pharmacology|October 29, 2013
Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgeryJens Juul Holst
Frontiers in Endocrinology|May 14, 2019
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes TherapyJens Juul Holst
Physiological Reviews|October 12, 2007
The physiology of glucagon-like peptide 1Jens Juul Holst
Pageof 40